Tag Archives: Experimental C diff treatments

Lee Jones, Rebiotix and Glenn Taylor, Taymount Clinic Discuss Fecal Microbiota Transplant (FMT) AKA Microbiota Restoration Therapy, Research to Clinical, on C diff Radio

cdiffRadioLogoMarch2015Join us on Tuesday, April 7th at 11:00 a.m.  Pacific / 2:00 p.m. Eastern Time

As guests, Ms. Lee Jones, CEO Rebiotix, Inc.  and Glenn Taylor, Microbiologist at Taymount Clinic  discuss

Fecal Microbiota Transplant (FMT) AKA Microbiota Restoration Therapy, Research to Clinical

 

 

Ms. Lee Jones, Founder, President and CEO of Rebiotix Inc, has over thirty years of experience in the medical technology industry in large and small companies and academia. Rebiotix is developing a new category of biologic drugs that use live human-derived organisms to treat disease. Lead candidate RBX2660 (microbiota suspension) is currently undergoing clinical study for recurrent C. diff. infection.

Mr. Glenn Taylor is the Microbiologist at the Taymount Clinic just outside London in the UK. He has spent five years researching the commensal colonization of bacteria in the human digestive system. Listen in as both guests discuss the Fecal or Faecal Microbiota Transplant (FMT),also known as Microbiota Restoration Therapy to treat recurrent C. diff. infections and more – Research to Clinical.

Each C. diff. Spores and More” episode becomes a pod-cast and can be easily accessed through our website:

https://cdifffoundation.org/c-diff-radio/

C. diff. Spores and More” spotlights world renown topic experts, research scientists, healthcare professionals, organization representatives, C. diff. survivors, board members, and their volunteers who are all creating positive changes in the C. diff. community and more.

Through their interviews, the CDF mission will connect, educate, and empower many in over 180 countries.

Questions received through the show page portal will be reviewed and addressed  by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP,  Dr. Fred Zar is a Professor of Clinical Medicine, Vice HeZarPhotoWebsiteTop (2)ad for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago.  Over the last two decades he has been a pioneer in the study of the treatment of Clostridium difficile disease and the need to stratify patients by disease severity.

 

Please join us Tuesdays in listening to the educational episodes of C. diff. Spores and More”

Take our show on the go…………..download a mobile app today

http://www.voiceamerica.com/company/mobileapps

 

 

 

 

 

 

 

 

 

 

 

 

 

 

C difficile infection; AdvancingBio in Mather, CA Provides a Resource For Healthcare Partners to Treat Patients With Recurrent C. diff. With Fecal Microbiota Transplant

A resource for patients seeking FMT information:

cdiffFMTimage

More than 350,000 cases of Clostridium difficile(C. diff), a dangerous and potentially fatal gastrointestinal bacterial infection, are diagnosed in the United States every year, killing over 15,000 people.

 

AdvancingBio, a not-for-profit organization that offers a treatment to patients suffering from C.diff, announces its launch with the opening of its stool collection and processing facility in Mather, CA, near Sacramento. The facility provides a unique resource for healthcare partners to treat patients with recurrent C. diff using Fecal Microbiota Transplant (FMT).

C. diff is a bacterium that can cause swelling and irritation of the large intestine, or colon. This inflammation, known as colitis, can lead to severe diarrhea, fever and abdominal cramps. The infection is most common in people who are taking antibiotics or have taken them recently, but it also can be transmitted to other people when they come into contact with infected patients or contaminated surfaces, especially if proper hygiene is not practiced.

“There is an emerging need for resources to treat patients suffering from C. difficile, which can be a very aggressive and life-threatening infection,” said Donny Dumani, MD, who oversees all medical aspects of AdvancingBio. “AdvancingBio was created with the mission to provide services to those in need. Our focus is to provide vital resources to healthcare partners who in turn perform fecal microbiota transplants to heal the growing number of patients with C. diff.”

FMT involves the transfer of a healthy microbiome, or the good bacteria present in carefully screened and tested donor stool, including the totality of microorganisms and their collective genetic material. FMT has been shown to deliver a 90+% cure rate.

The donor screening and donation process takes approximately less than 30 minutes. Donors will receive pre-donation educational material and instructions, then proceed to a confidential medical history review by a licensed AdvancingBio staff member. A blood draw will be conducted for infectious disease testing, and then the donor will be provided a clean, private facility for the donation. Eligibility requirements to donate stool are assessed at the time of donation and include feeling well and healthy, being free from cold and flu-like symptoms for 14 days, being between 18 – 65 years old and having a Body Mass Index less than 35.

“The immediate availability of thoroughly screened products that meet the current FDA requirements for our patients with recurring C. difficile is more than welcome,” said R. Erick Pecha, MD, partner at Gastroenterology Medical Clinic in Folsom. “It is long overdue.”

AdvancingBio is open to donors Monday through Friday, from 7:30 a.m. – 1:30 p.m. PT. For more information or to become a donor, please visit advancingbio.org or call (844) 426-7264.

About AdvancingBio
Established in 2015, AdvancingBio is a not-for-profit organization that operates a stool collection and processing facility which provides a unique resource for healthcare partners to treat the growing number of patients suffering from Clostridium difficile infection (C. diff). More than 350,000 cases of C. diff are diagnosed in the U.S. every year, and over 15,000 people die each year from this aggressive bacterial infection. Schedule an appointment or learn more at 844.426.7264 or advancingbio.org